Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$12.27
-$0.09(-0.63%)
At close: 4:00 PM EDT
$12.27
-$0.09(-0.63%)
Day’s Range― - ―
52-Week Range$6.99 - $33.20
Previous Close$14.12
Volume694.64K
Average Volume (3M)655.28K
Market Cap
$299.77M
Enterprise Value$288.08
Total Cash (Recent Filing)$200.79M
Total Debt (Recent Filing)$8.11M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Dec 10, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding36,292,114
10 Day Avg. Volume752,047
30 Day Avg. Volume655,278
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.00Price Target Upside95.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$3.13M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has grown substantially over three reported years, indicating increasing commercial or collaboration activity despite the company’s clinical-stage profile. If this trajectory continues, a larger revenue base could improve operating leverage and help support investment in Evommune’s pipeline.
Balance Sheet StrengthThe sharp reduction in debt and swing to positive equity materially strengthen financial flexibility and reduce leverage risk. This gives Evommune a more durable capital structure for advancing clinical programs, although continued operating losses mean disciplined funding remains important.
EVO301 Clinical Proof Of ConceptPositive Phase 2a efficacy, durable responses after two doses, broad biomarker activity, and favorable tolerability provide meaningful validation for EVO301’s IL-18 approach. These results strengthen the lead program and support further development in atopic dermatitis and potentially related inflammatory diseases.
Bears Say
Persistent Net LossesLarge and persistent net losses show that Evommune’s current revenue base remains far below the cost of operating and developing its programs. Unless revenue scales materially or expenses decline, profitability is unlikely to provide near-term internal funding for pipeline expansion.
Escalating Cash BurnDeepening operating and free-cash-flow deficits increase the company’s ongoing funding burden while clinical development continues. Higher cash consumption can reduce the duration of financial flexibility and may require tighter spending controls or additional capital before products generate meaningful revenue.
EVO756 Atopic Dermatitis FailureThe failed Phase 2b study removes EVO756 from Evommune’s atopic dermatitis strategy and narrows the near-term pipeline in that indication. It also demonstrates clinical execution risk, leaving greater dependence on EVO301 and the still-unproven migraine program for future progress.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $6.99 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $299.77M.
When is Evommune, Inc.’s upcoming earnings report date?
Evommune, Inc.’s upcoming earnings report date is Dec 10, 2026 which is in 69 days.
How were Evommune, Inc.’s earnings last quarter?
Evommune, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.664 by -$0.226.
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,292,114 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Evommune, Inc. reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.664. Following the earnings report the stock price went up 5.232%.
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (95.60% Upside)
$24.00 (95.60% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 448.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $146.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
213.84%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$24.00
▲(95.60% Upside)
Technical Analysis
Ownership Overview
52.09% Insiders
11.50% Mutual Funds
29.89% Other Institutional Investors
1.47% Public Companies and
Individual Investors